Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - human chorionic gonadotrophin, quantity: 5000 iu - injection, powder for - excipient ingredients: dibasic sodium phosphate dihydrate; monobasic sodium phosphate dihydrate; carmellose sodium; mannitol - in the female: sterility due to the absence of follicle-ripening or ovulation.,in the male: hypogonadotrophic hypogonadism. delayed puberty associated with insufficient gonadotrophic pituitary function. cryptorchism, not due to an anatomic obstruction. sterility, in cases of deficient spermatogenesis.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - human chorionic gonadotrophin, quantity: 1500 iu - injection, powder for - excipient ingredients: monobasic sodium phosphate dihydrate; mannitol; dibasic sodium phosphate dihydrate; carmellose sodium - in the female: sterility due to the absence of follicle-ripening or ovulation.,in the male: hypogonadotrophic hypogonadism. delayed puberty associated with insufficient gonadotrophic pituitary function. cryptorchism, not due to an anatomic obstruction. sterility, in cases of deficient spermatogenesis.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - follitropin alfa, quantity: 150 iu; lutropin alfa, quantity: 75 iu - injection, powder for - excipient ingredients: sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate; methionine; polysorbate 20; phosphoric acid; sodium hydroxide - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - leuprorelin acetate, quantity: 30 mg - injection, modified release - excipient ingredients: mannitol; polylactic acid - lucrin depot paediatric 30 mg 3-month pds injection is indicated in the treatment of children with central precocious puberty (cpp).

Canada - English - Health Canada

fresenius kabi canada ltd - chorionic gonadotropin - powder for solution - 10000unit - chorionic gonadotropin 10000unit - gonadotropins and antigonadotropins

Australia - English - Department of Health (Therapeutic Goods Administration)

abraxis bioscience australia pty ltd - paclitaxel, quantity: 100 mg - injection, powder for - excipient ingredients: albumin; sodium octanoate; sodium acetyltryptophanate - metastatic breast cancer abraxane is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. non-small cell lung cancer abraxane, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation. metastatic adenocarcinoma of the pancreas abraxane, in combination with gemcitabine, is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.

Australia - English - Department of Health (Therapeutic Goods Administration)

abraxis bioscience australia pty ltd - paclitaxel, quantity: 250 mg - injection, powder for - excipient ingredients: albumin; sodium octanoate; sodium acetyltryptophanate - metastatic breast cancer abraxane is indicated for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. non-small cell lung cancer abraxane, in combination with carboplatin, is indicated for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation. metastatic adenocarcinoma of the pancreas abraxane, in combination with gemcitabine, is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas.

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - leuprorelin acetate, quantity: 7.5 mg - injection, modified release - excipient ingredients: gelatin; mannitol; polyglactin - lucrin depot 7.5 mg injection and lucrin depot 3 month 22.5mg injection and lucrin depot 4 month 30mg injection are indicated in the palliative treatment of metastatic or locally extensive prostatic cancer (stage c and d).

Ireland - English - HPRA (Health Products Regulatory Authority)

intervet ireland limited - chorionic gonadotrophin - powder and solvent for solution for injection - 1500 international unit(s) - chorionic gonadotrophin - cattle, dogs, horses - hormone

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - cetrorelix, quantity: 0.25 mg - injection, powder for - excipient ingredients: mannitol - indications: prevention of premature luteinization and ovulation in patients undergoing a controlled ovarian stimulation, followed by oocyte pick up and assisted reproductive techniques. in clinical trials cetrotide was used with human menopausal gonadotrophin (hmg), however limited experience with recombinant fsh suggested similar efficacy.